MONT-SAINT-GUIBERT, Belgium, May 19, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD...
Celyad intends to leverage this designation to accelerate the search for a strategic partnerDesignation...
MONT-SAINT-GUIBERT, Belgium, March 16, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD...
Opening of the hematological arm of the CAR-T NKR-2 THINK trial with first Multiple Myeloma patient.No toxic...
Celyad Announces Positive New Data from its CAR-T NKR-2 Phase I Trial at 2016 ASH Annual Meeting Strong safety signals, including no cases...
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the...
First clinical trial of NKR-2 T-cells therapy completed with good safety outcome and unexpected signals of clinical activity at the low doses...
MONT-SAINT-GUIBERT, Belgium, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the...
MONT-SAINT-GUIBERT, Belgium, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery...
Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level No safety issues or dose limiting...
MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery...
No safety issues or dose limiting toxicity reported in the first patient at the fourth dose level. Next patient, 11th of the trial, has...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.